Adaptimmune GAAP EPS of -$0.01 beats by $0.07, revenue of $40.9M beats by $20.41M

Adaptimmune press release ( NASDAQ: ADAP ): Q3 GAAP EPS of -$0.01 beats by $0.07 .

Revenue of $40.9M (+460.3% Y/Y) beats by $20.



41M . Shares +3.83% AH.

More on Adaptimmune Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions Adaptimmune to engage in restructuring; 33% headcount reduction Adaptimmune reports positive data in mid-stage trial of its sarcoma treatment Seeking Alpha’s Quant Rating on Adaptimmune Historical earnings data for Adaptimmune.